Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals: Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes long and presents 5–6 recently published articles. Intended for the busy health care professional who has little time to review journal articles in depth, Diabetes Core Update discusses how the latest research and information published in ADA journals are relevant to clinical practice and can be applied in a treatment setting.
Diabetes Core Update podcasts are free and can be accessed through Apple Podcasts, Google Play or RSS feed. For more information about RSS feeds, see ADA Journals RSS Feeds. The podcasts are also accessible for listening on your computer or mobile device and can be downloaded below.
Latest Podcasts |
|
|
Diabetes Core Update October 2021 Post Date: October 11, 2021 |
Discussed in This EpisodeReplacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. Li et al. Diabetes Care 2021 Oct; 44(10): 2403-2410. https://doi.org/10.2337/dc21-0455. Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. den Braber et al. Diabetes Care 2021 Oct; 44(10): 2238-2244. https://doi.org/10.2337/dc20-2241. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Harris et al. Diabetes Care 2021 Oct; 44(10): 2293-2301. https://doi.org/10.2337/dc21-0529. Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Lind et al. Diabetes Care 2021 Oct; 44(10): 2231-2237. https://doi.org/10.2337/dc20-2439. Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. Gyldenkerne et al. Diabetes Care 2021 Oct; 44(10): 2353-2360. https://doi.org/10.2337/dc21-0383. |
|
Special Diabetes Core Update: SGLT2 Inhibitors and Diabetic Kidney Disease Post Date: September 27, 2021 |
Discussed in This EpisodeAmerican Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167. doi: 10.2337/dc21-S011. Erratum in: Diabetes Care. 2021 Sep;44(9):2186-2187. PMID: 33298422. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511. PMID:33031522; PMCID: PMC7542529. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396. Stempniewicz N, Vassalotti JA, Cuddeback JK, Ciemins E, Storfer-Isser A, Sang Y, Matsushita K, Ballew SH, Chang AR, Levey AS, Bailey RA, Fishman J, Coresh J. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care. 2021 Sep;44(9):2000-2009. doi: 10.2337/dc20-2715. Epub 2021 Jul 7. PMID: 34233925. Alfego D, Ennis J, Gillespie B, Lewis MJ, Montgomery E, Ferrè S, Vassalotti JA, Letovsky S. Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Diabetes Care. 2021 Sep;44(9):2025-2032. doi: 10.2337/dc21-0723. Epub 2021 Aug 5. PMID: 34353883. Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, and Koitka-Weber A. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 Mar;99(3):750-762. doi: 10.1016/j.kint.2020.10.031. Epub 2020 Nov 10. PMID: 33181154. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int. 2021 Apr;99(4):999-1009. doi: 10.1016/j.kint.2020.10.042. Epub 2020 Dec 11. PMID: 33316282. Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018 Nov 1;33(11):2005-2011. PMID: 29370424; PMCID: PMC6212718. |
|
Diabetes Core Update September 2021 Post Date: August 26, 2021 |
Discussed in This EpisodeTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías et al. N Engl J Med 2021; 385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Stempniewicz et al. Diabetes Care 2021 Sep; 44(9): 2000-2009. https://doi.org/10.2337/dc20-2715. Nutritional basis of type 2 diabetes remission. Taylor et al. BMJ 2021;374:n1449. https://doi.org/10.1136/bmj.n1449. Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Alfego et al. Diabetes Care 2021 Sep; 44(9): 2025-2032. https://doi.org/10.2337/dc21-0723. Preparing for the NASH Epidemic: A Call to Action. Kanwal et al. Diabetes Care 2021 Sep; 44(9): 2162-2172. https://doi.org/10.2337/dci21-0020. Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Gregg et al. Diabetes Care 2021 Sep; 44(9): 1916-1923. https://doi.org/10.2337/dci21-0001. |
|
Diabetes Core Update August 2021 Post Date: July 28, 2021 |
Discussed in This EpisodeHigh Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999–2017. Park et al. Diabetes Care 2021 Aug; 44(8): 1797-1804. https://doi.org/10.2337/dc20-2708. Affect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Martens T, Beck RW, Bailey R, et al. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. JAMA. 2021;325(22):2273–2284. doi:10.1001/jama.2021.6530. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. Fang et al. N Engl J Med 2021; 384:2219-2228. DOI: 10.1056/NEJMsa2032271. Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. Salem et al. Diabetes Care 2021 Aug; 44(8): 1842-1851. https://doi.org/10.2337/dc20-2641. The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes Care 2021 Aug; 44(8): 1734-1743. https://doi.org/10.2337/dci21-0015. The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes 2021 Aug; 70(8): 1623-1633. https://doi.org/10.2337/db21-0052. |
|
Diabetes Core Update July 2021 Post Date: July 5, 2021 |
Discussed in This EpisodeHigh Burden of Subclinical and Cardiovascular Disease Risk in Adults with Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Commodore-Mensah et al. Diabetes Care 2021 Jul; 44 (7): 1657-1663. https://doi.org/10.2337/dc20-2227. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Lingvay et al. Diabetes Care 2021 Jul; 44(7): 1595-1603. https://doi.org/10.2337/dc20-2878. Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes. Nurminen et al. Diabetes Care 2021 Jul; 44(7): 1506-1514. https://doi.org/10.2337/dc20-1719. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Bajaj et al. Diabetes Care 2021 Jul; 44(7): 1586-1594. https://doi.org/10.2337/dc20-2877. Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Morton et al. Diabetes Care 2021 Jul; 44(7): 1515-1523. https://doi.org/10.2337/dc21-0220. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Walker et al. Diabetes Care 2021 Jul; 44(7): 1480-1490. https://doi.org/10.2337/dc20-2753. |
|
Diabetes Core Update June 2021 Post Date: May 25, 2021 |
Discussed in This EpisodeApplication of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Colling et al. Diabetes Care 2021 June; 44(6): 1443-1446. https://doi.org/10.2337/dc21-0013. Important Drop Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Roussel et al. Diabetes Care 2021 June; 44(6): 1368-1376. https://doi.org/10.2337/dc20-1690. Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes. Homer et al. Diabetes Care 2021 June; 44(6): 1254-1263. https://doi.org/10.2337/dc20-1410. Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants. Claessen et al. Diabetes Care 2021 June; 44(6): 1291-1299. https://doi.org/10.2337/dc20-2477. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Giugliano et al. Diabetes Care 2021 June; 44(6): 1353-1360. https://doi.org/10.2337/dc20-2623. Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials. Silverii et al. Diabetes Obes Metab. 2021; 23: 1052– 1056. https://doi.org/10.1111/dom.14286. |
|
Post Date: April 26, 2021 |
Discussed in This EpisodeBody Weight Changes During Pandemic-Related Shelter-in-Place in a Longitudinal Cohort Study. Lin et al. JAMA Netw Open. 2021;4(3):e212536. doi:10.1001/jamanetworkopen.2021.2536. Risk of Progression to Diabetes Among Older Adults With Prediabetes. Rooney et al. JAMA. JAMA Intern Med. 2021;181(4):511-519. doi:10.1001/jamainternmed.2020.8774. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn et al. Diabetes Care 2021 May; 44(5): 1159-1167. https://doi.org/10.2337/dc20-2492. Associations of Diet Quality and All-Cause Mortality Across Levels of Cardiometabolic Health and Disease: A 7.6-Year Prospective Analysis From the Dutch Lifelines Cohort. Vinke et al. Diabetes Care 2021 May; 44(5): 1228-1235. https://doi.org/10.2337/dc20-2709. Associations Between Exposure to Gestational Diabetes Mellitus In Utero and Daily Energy Intake, Brain Responses to Food Cues, and Adiposity in Children. Luo et al. Diabetes Care 2021 May; 44(5): 1185-1193. https://doi.org/10.2337/dc20-3006. Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Bancks et al. Diabetes Care 2021 May; 44(5): 1203-1210. https://doi.org/10.2337/dc20-2372. |
|
Diabetes Core Update April 2021 Post Date: March 26, 2021 |
Discussed in This EpisodeOnce-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding et al. N Engl J Med 2021; 384:989-1002. doi: 10.1056/NEJMoa2032183. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial. Wadden TA, Bailey TS, Billings LK, et al. JAMA. Published online February 24, 2021. doi:10.1001/jama.2021.1831. Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Ling et al. Diabetes Care 2021 Apr; 44(4): 915-924. https://doi.org/10.2337/dc20-0876. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Persson et al. Diabetes Care 2021 Apr; 44(4): 1020-1026. https://doi.org/10.2337/dc20-1622. Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. Kammerlander et al. Diabetes Care 2021 Apr; 44(4): 1038-1045. https://doi.org/10.2337/dc20-1760. Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes. Qian et al. Diabetes Care 2021 Apr; 44(4): 1046-1054. https://doi.org/10.2337/dc20-2178. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Dave et al. Circulation. 2021;143:770–779. https://doi.org/10.1161/CIRCULATIONAHA.120.047965. |
|
Diabetes Core Update: SGLT2 Inhibitors Series, Episode #3 Post Date: March 12, 2021 |
Discussed in This EpisodeIn the third and final episode of this special series on "SGLT2 Inhibitors in Type 2 Diabetes: Cardiovascular & Renal Outcomes," Drs. Skolnik and Russell discuss the most recent large-scale trials that have focused on the cardiovascular effects associated with SGLT2 inhibitors, how the outcomes of those trials have influenced the latest treatment guidelines related to cardiovascular disease and risk management in patients with type 2 diabetes, and how SGLT2 inhibitors should be sequenced in the treatment of patients with type 2 diabetes and cardiovascular complications. Over the course of their discussion, Drs. Skolnik and Russell refer to the following articles: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. Wanner C, Inzucchi SE, Lachin JM, et al., for the EMPA-REG OUTCOME Investigators. N Engl J Med. 2016 Jul 28;375(4):323-34. doi:10.1056/NEJMoa1515920. PMID: 27299675. Section 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. American Diabetes Association. Diabetes Care. 2021 Jan; 44(Supplement 1):S125-150. doi:10.2337/dc21-S010. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. Das SR, Everett BM, Birtcher KK, Brown JM, et al. Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi:10.1016/j.jacc.2020.05.037. PMID: 32771263; PMCID: PMC7545583. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, et al., for the DECLARE–TIMI 58 Investigators. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. PMID: 30415602. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. Packer M, Anker SD, Butler J, et al., for the EMPEROR-Reduced Trial Investigators. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi:10.1056/NEJMoa2022190. PMID: 32865377. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, et al.. J Am Coll Cardiol. 2021 Feb 16;77(6):772-810. doi:10.1016/j.jacc.2020.11.022. PMID: 33446410. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. McMurray JJV, Packer M. Circulation. 2021 Mar 2;143(9):875-877. doi:10.1161/CIRCULATIONAHA.120.052926. PMID: 33378214. Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. Pandey A, Vaduganathan M, Patel KV, Ayers C, et al. JACC Heart Fail. 2021 Mar;9(3):215-223. doi:10.1016/j.jchf.2020.10.013. PMID: 33422434. This special series of Diabetes Core Update is supported by an unrestricted educational grant from the Division of Cardiovascular & Metabolic Diseases of U.S. Medical at AstraZeneca Pharmaceuticals, LP. All material is intended for medical education purposes only and contains no promotional information. |
|
Diabetes Core Update March 2021 Post Date: February 28, 2021 |
Discussed in This EpisodeEfficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Frias et al. Diabetes Care 2021 Mar; 44(3): 765-773. https://doi.org/10.2337/dc20-1473 The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Wolf et al. Diabetes Care 2021 Mar; 44(3): 781-787. https://doi.org/10.2337/dc20-1671 Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Islam et al. Diabetes Care 2021 Mar; 44(3): 757-764. https://doi.org/10.2337/dc20-1213 Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Blonde et al. Diabetes Care 2021 Mar; 44(3): 774-780. https://doi.org/10.2337/dc20-2023 Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Patorno et al. Diabetes Care 2021 Mar; 44(3): 826-835. https://doi.org/10.2337/dc20-1464 Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. Chen et al. Diabetes Care 2021 Mar; 44(3): 663-671. https://doi.org/10.2337/dc20-1636 |
Diabetes Core Update: Diabetes Technology-- February 2021 Post Date: February 11, 2021 |
Discussed in This EpisodeIn this special edition podcast, three diabetes experts discuss the potential for improvement in care of persons with diabetes with the use of diabetes technology. This special edition is supported by unrestricted educational grants to the American Diabetes Association from Abbott Diabetes Care and Dexcom. For more information about the articles discussed, please see the special edition of Clinical Diabetes, Special topic: Diabetes Technology in Primary Care. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health. Mansur Shomali, M.D., founding physician of the Diabetes & Endocrine Center at MedStar Union Memorial Hospital in Baltimore, MD, Adjunct Associate Professor of Medicine at the University of Maryland School of Medicine in Baltimore, and Chief Medical Officer at Welldoc. Eden Miller, D.O., Executive Director and Co-Founder of Diabetes Nation and in practice at Diabetes and Obesity Care, St. Charles Hospital, Bend, Oregon. Eugene Wright, M.D. Medical Director for Performance Improvement at the Charlotte Area Health Education Center. |
|
Diabetes Core Update February 2021 Post Date: January 27, 2021 |
Discussed in This EpisodeTime in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Lu et al. Diabetes Care 2021 Feb; 44(2): 549-555. https://doi.org/10.2337/dc20-1862 Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Lomonaco et al. Diabetes Care 2021 Feb; 44(2): 399-406. https://doi.org/10.2337/dc20-1997 Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Abdul-Ghani et al. Diabetes Care 2021 Feb; 44(2): 433-439. https://doi.org/10.2337/dc20-0978 Glycemic Control and Risk of Cellulitis. Zacay et al. Diabetes Care 2021 Feb; 44(2): 367-372. https://doi.org/10.2337/dc19-1393 Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Inzucchi et al. Diabetes Care 2021 Feb; 44(2): 586-594. https://doi.org/10.2337/dc20-1675 Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes. Wan et al. Diabetes Care 2021 Feb; 44(2): 350-357. https://doi.org/10.2337/dc20-1485 |
|
Diabetes Core Update January 2021 Post Date: December 27, 2020 |
Discussed in This EpisodeOnce-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. Rosenstock et al. N Engl J Med 2020; 383:2107-2116. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022474 The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study. Singh et al. Diabetes Care 2021 Jan; 44(1): 116-124. https://doi.org/10.2337/dc20-0571 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt et al. N Engl J Med November 16, 2020.DOI: 10.1056/NEJMoa2030186 Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015. Cheng et al. Diabetes Care 2021 Jan; 44(1): 89-97. https://doi.org/10.2337/dc20-1913 Sedentary Time and Metabolic Risk in Extremely Active Older Adults. Madden et al. Diabetes Care 2021 Jan; 44(1): 194-200. https://doi.org/10.2337/dc20-0849 Severe Hypoglycemia, Cardiac Structure and Function, and Risk of Cardiovascular Events Among Older Adults With Diabetes. Echouffo-Tcheugui et al. Diabetes Care 2021 Jan; 44(1): 248-254. https://doi.org/10.2337/dc20-0552 |
|
Diabetes Core Update: Diabetes and Influenza Series Episode #3 Post Date: December 17, 2020 |
Discussed in This EpisodeIn the third episode of this special three-part series, Drs. Skolnik and Russell address frequently asked questions related influenza, influenza vaccines, how influenza affects people with diabetes, and how health care providers can encourage their patients to get an influenza vaccination. In the course of their discussion, Drs. Skolnik and Russell refer to the following studies: MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016 Dec 15;102(24):1953-1956. doi:10.1136/heartjnl-2016-309983. Epub 2016 Sep 29. PMID: 27686519. Warren-Gash C, Blackburn R, Whitaker H, et al. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018 Mar 29;51(3):1701794. doi:10.1183/13993003.01794-2017. PMID: 29563170; PMCID: PMC5898931. Dunkle LM, Izikson R, Patriarca P, et al., for the PSC12 Study Team. Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older. N Engl J Med. 2017 Jun 22;376(25):2427-2436. doi:10.1056/NEJMoa16088627. PMID: 28636855. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45. doi:10.1056/NEJMoa131572. PMID: 25119609. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015 Mar;15(3):293-300. doi:10.1016/S1473-3099(14)71087-4. PMID: 25672568. This episode concludes this special three-part series on influenza and diabetes. Diabetes Core Update and the American Diabetes Association thank Sanofi Pasteur, the vaccines global business unit of Sanofi, which supported this series through an unrestricted educational grant. |
|
Diabetes Core Update: SGLT2 Inhibitors Series, Episode #2 Post Date: December 3, 2020 |
Discussed in This EpisodeIn the second episode of this special three-part series on "SGLT2 Inhibitors in Type 2 Diabetes: Cardiovascular & Renal Outcomes," Drs. Skolnik and Russell examine the outcomes of several important clinical trials on the renal effects of SGLT2 inhibitors: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. Wanner C, Inzucchi SE, Lachin JM, et al., for the EMPA-REG OUTCOME Investigators. N Engl J Med. 2016 Jul 28;375(4):323-34. doi:10.1056/NEJMoa1515920. PMID: 27299675 Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Neal B, Perkovic V, Mahaffey KW, et al., for the CANVAS Program Collaborative Group. N Engl J Med. 2017 Aug 17;377(7):644-657. doi:10.1056/NEJMoa1611925. PMID: 28605608 Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, et al., for the DECLARE–TIMI 58 Investigators. N Engl J Med. 2019 Jan 24;380(4):347-357. doi:10.1056/NEJMoa1812389. PMID: 30415602 Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. PMID: 32966714 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Perkovic V, Jardine MJ, Neal B, et al., for the CREDENCE Trial Investigators. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi:10.1056/NEJMoa1811744. PMID: 30990260 Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. McMurray JJV, Solomon SD, Inzucchi SE, et al., for the DAPA-HF Trial Committees and Investigators. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi:10.1056/NEJMoa1911303. PMID: 31535829 Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Kosiborod MN, Jhund PS, Docherty KF, et al. Circulation. 2020 Jan 14;141(2):90-99. doi:10.1161/CIRCULATIONAHA.119.044138. PMID: 31736335 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. Packer M, Anker SD, Butler J, et al., for the EMPEROR-Reduced Trial Investigators. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi:10.1056/NEJMoa2022190. PMID: 32865377 Dapagliflozin in Patients with Chronic Kidney Disease. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al., for the DAPA-CKD Trial Committees and Investigators. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi:10.1056/NEJMoa2024816. PMID: 32970396 In episode 3 of this series, Drs. Skolnik and Russell will take a closer look into the cardiovascular effects associated with SGLT2 inhibitors and will discuss the practical aspects and clinical implications of their use in the treatment of patients with type 2 diabetes. This special series of Diabetes Core Update is supported by an unrestricted educational grant from the Division of Cardiovascular & Metabolic Diseases of U.S. Medical at AstraZeneca Pharmaceuticals, LP. All material is intended for medical education purposes only and contains no promotional information. |
|
Diabetes Core Update December 2020 Post Date: November 24, 2020 |
Discussed in This EpisodeCardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. Packer et al. N Engl J Med 2020; 383:1413-1424. 10.1056/NEJMoa2022190 Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Mirani et al. Diabetes Care 2020 Dec; 43(12): 3042-3049. https://doi.org/10.2337/dc20-1340 Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19 Seiglie et al. Diabetes Care 2020 Dec; 43(12): 2938-2944. https://doi.org/10.2337/dc20-1506 Changes in Statin Use Among U.S. Adults With Diabetes: A Population-Based Analysis of NHANES 2011–2018. Leino et al. Diabetes Care 2020 Dec; 43(12): 3110-3112. https://doi.org/10.2337/dc20-1481 Dapagliflozin in Patients with Chronic Kidney Disease. Heerspink et al. N Engl J Med 2020; 383:1436-1446. 10.1056/NEJMoa2024816 |
|
Diabetes Core Update: Therapeutic Inertia Series Episode #3 Post Date: November 5 2020 |
Discussed in This EpisodeIn this third and final episode of the Diabetes Core Update series on “Disrupting Therapeutic Inertia in Diabetes Management,” Dr. Neil Skolnik focuses on practical solutions for overcoming therapeutic inertia. To do so, Dr. Skolnik discusses various strategies and approaches with four master physicians, each of whom provide a unique perspective on how to address therapeutic inertia in the treatment of diabetes: Dr. Eric L. Johnson discusses the importance of understanding and being familiar with the ADA/EASD algorithm for prescribing and adjusting medications, as well as the importance of planning and communicating next steps with patients at each visit. Dr. William H. Polonsky discusses the importance of creating a sense of urgency around treatment and management, as well as strategies for developing trust with patients in order to guide them to better adherence and diabetes management. Dr. Pamela R. Kushner discusses the importance of a team approach to managing patients with diabetes, as well as the usefulness of free patient resources that can help patients with diabetes, including ADA’s Living with Type 2 Diabetes program. Dr. Steven V. Edelman discusses the importance of empathizing with patients, of understanding and acknowledging the difficulties related to managing diabetes, in order to encourage patients to better adhere to their treatment protocols. This episode concludes the special three-part series on therapeutic inertia. This series is supported by an independent educational grant from Sanofi. |
|
Diabetes Core Update November 2020 Post Date: October 27, 2020 |
Discussed in This EpisodeChildhood BMI and Fasting Glucose and Insulin Predict Adult Type 2 Diabetes: The International Childhood Cardiovascular Cohort (i3C) Consortium. Hu et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc20-0822 Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen. Galindo et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc19-2073 Has COVID-19 Delayed the Diagnosis and Worsened the Presentation of Type 1 Diabetes in Children? Rabbone et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc20-1321 Reducing Inpatient Hypoglycemia in the General Wards Using Real-Time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial. Singh et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc20-0840 A Shift Toward a Plant-Centered Diet From Young to Middle Adulthood and Subsequent Risk of Type 2 Diabetes and Weight Gain: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Choi et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc20-1005 Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting. Choi et al. Diabetes Care 2020 Nov; 43(11). https://doi.org/10.2337/dc20-1016 |
|
Diabetes Core Update October 2020 Post Date: October 12, 2020 |
Discussed in This EpisodeThe Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial. Sabag et al. Diabetes Care 2020 Oct; 43(10). https://doi.org/10.2337/dc19-2523 Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Rosenstock et al. Diabetes Care 2020 Oct; 43(10). https://doi.org/10.2337/dc19-2316 Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study. Thabit et al. Diabetes Care 2020 Oct; 43(10). https://doi.org/10.2337/dc20-0736 Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Jabbour et al. Diabetes Care 2020 Oct; 43(10). https://doi.org/10.2337/dc19-1350 Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. Longato E, Di Camillo B, Sparacino G, et al. BMJ Open Diabetes Research and Care 2020;8:e001451. doi: 10.1136/bmjdrc-2020-001451 Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Yun Yu et al. Diabetes Care 2020 Oct; 43(10). https://doi.org/10.2337/dc20-0267 |
|
Diabetes Core Update: Diabetes and Influenza Series Episode #2 Post Date: September 29, 2020 |
Discussed in This EpisodeIn the second episode of this special three-part series, Drs. Skolnik and Russell discuss the impact of influenza on people with diabetes and, thus, the importance of getting an influenza vaccination for people with diabetes. Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006 Aug;29(8):1771-6. doi: 10.2337/dc05-2517. PMID: 16873778 Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. CMAJ. 2016 Oct 4;188(14):E342-E351. doi: 10.1503/cmaj.151059. Epub 2016 Jul 25. PMID: 27455981; PMCID: PMC5047834. Modin D, Claggett B, Køber L, Schou M, Jensen JUS, Solomon SD, Vardeny O, Knop FK, Nielsen SD, Fralick M, Torp-Pedersen C, Gislason G, Biering-Sørensen T. Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2020 Sep;43(9):2226-2233. doi: 10.2337/dc20-0229. PMID: 32647052. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015 Nov;101(21):1738-47. doi: 10.1136/heartjnl-2015-307691. Epub 2015 Aug 26. PMID: 26310262; PMCID: PMC4680124. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45. doi: 10.1056/NEJMoa1315727. PMID: 25119609. In episode 3, Drs. Skolnik and Russell will discuss the important role that clinicians play in improving vaccination rates among patients with diabetes. This special three-part series on influenza and diabetes is supported by an unrestricted educational grant from Sanofi Pasteur, the vaccines global business unit of Sanofi. |
|
Diabetes Core Update: SGLT2 Inhibitors Series, Episode #1 Post Date: September 11, 2020 |
Discussed in This EpisodeIn the first episode of this special three-part series on "SGLT2 Inhibitors in Type 2 Diabetes: Cardiovascular & Renal Outcomes," Drs. Skolnik and Russell review in detail the dramatic results from the following clinical trials: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720. PMID: 26378978 Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925. PMID: 28605608 Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389. PMID: 30415602 Study summary: Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial - VERTIS CV. Posted 31 August 2020. https://www.acc.org/latest-in-cardiology/clinical-trials/2020/06/16/11/24/vertis In episodes 2 and 3 of this series, Drs. Skolnik and Russell will take a closer look into the cardiorenal effects associated with SGLT2 inhibitors and will discuss the practical aspects and clinical implications of their use in the treatment of patients with type 2 diabetes. This special three-part series on SGLT2 inhibitors is supported by an unrestricted educational grant from AstraZeneca. |
|
Diabetes Core Update September 2020 Post Date: September 1, 2020 |
Discussed in This EpisodeBody Weight Variability and the Risk of Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes: A Nationwide Cohort Study. Nam et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc19-2552 Health Care Utilization of Homeless Minors With Diabetes in New York State From 2009 to 2014. Sakai-Bizmark et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc19-2219 The Affordable Care Act: Effects of Insurance on Diabetes Biomarkers. Marino et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc19-1571 Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. Gokhale et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc19-1880 Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Deshmukh et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc20-0738 Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. Modin et al. Diabetes Care 2020 Sept; 43(9). https://doi.org/10.2337/dc20-0229 |
|
Diabetes Core Update August 2020 Post Date: August 10, 2020 |
Discussed in This EpisodeThe Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Ilkun et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc19-2047 Effects of an Electronic Software “Prompt” With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial. Willis et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc19-2243 A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Lane et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc19-2232 Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study. Adderley et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc19-2116 Social Support, Social Network Size, Social Strain, Stressful Life Events, and Coronary Heart Disease in Women With Type 2 Diabetes: A Cohort Study Based on the Women’s Health Initiative. Jonasson et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc19-2065 Whole-Grain Processing and Glycemic Control in Type 2 Diabetes: A Randomized Crossover Trial. Åberg et al. Diabetes Care 2020 Aug; 43(8). https://doi.org/10.2337/dc20-0263 |
|
Diabetes Core Update: Therapeutic Inertia Series Episode #2 Post Date: July 30, 2020 |
Discussed in This EpisodeIn this second episode of a three-part series on “Disrupting Therapeutic Inertia in Diabetes Management,” Drs. John Russell and Neil Skolnik are joined by Dr. Stewart Harris of the Schulich School of Medicine and Dentistry, Western University (Toronto, ON), to discuss the causes and consequences of therapeutic inertia. In so doing, Drs. Russell, Skolnik, and Harris refer to the following publications: The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. Diabetes Care. 2019 Mar;42(3):416-426. https://doi.org/10.2337/dc17-1144. Epub 2018 Aug 13. PMID: 30104301; PMCID: PMC6385699. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Cardiovasc Diabetol. 2015 Aug 7;14:100. doi: 10.1186/s12933-015-0260-x. PMID: 26249018; PMCID: PMC4528846. Therapeutic Inertia in People With Type 2 Diabetes in Primary Care: A Challenge That Just Won't Go Away. Zhu NA, Harris SB. Diabetes Spectr. 2020 Feb;33(1):44-49. doi: 10.2337/ds19-0016. PMID: 32116453; PMCID: PMC7026753. Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care. Harris SB, Cheng AYY, Davies MJ, Gerstein HC, Green JB, Skolnik N. Arlington (VA): American Diabetes Association; 2020 May. PMID: 32667763. In episode 3, Drs. Russell and Skolnik will conclude this special series by examining solutions for overcoming therapeutic inertia. This special three-part series on therapeutic inertia is supported by independent educational grant from Sanofi. |
|
Diabetes Core Update July 2020 Post Date: July 4, 2020 |
Discussed in This EpisodeAdolescent Obesity and Early-Onset Type 2 Diabetes. Twig et al. Diabetes Care 2020 July; 43(7). https://doi.org/10.2337/dc19-1988 Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial. Vilsbøll, T, Ekholm, E, Johnsson, E, et al. Diabetes Obes Metab. 2020; 22: 957– 968. https://doi.org/10.1111/dom.13981 Clinical and Public Health Implications of 2019 Endocrine Society Guidelines for Diagnosis of Diabetes in Older Adults. Fang et al. Diabetes Care 2020 July; 43(7). https://doi.org/10.2337/dc19-2467 Effectiveness of herbal medicines for weight loss: A systematic review and meta‐analysis of randomized controlled trials. Maunder, A, Bessell, E, Lauche, R, Adams, J, Sainsbury, A, Fuller, NR. Diabetes Obes Metab. 2020; 22: 891– 903. https://doi.org/10.1111/dom.13973 The Association of Energy and Macronutrient Intake at Dinner Versus Breakfast With Disease-Specific and All-Cause Mortality Among People With Diabetes: The U.S. National Health and Nutrition Examination Survey, 2003–2014. Han et al. Diabetes Care 2020 July; 43(7). https://doi.org/10.2337/dc19-2289 Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Powers et al. Diabetes Care 2020 July; 43(7). https://doi.org/10.2337/dci20-0023 |
|
Diabetes Core Update: Diabetes and Influenza Series Episode #1 Post Date: June 23, 2020 |
Discussed in This EpisodeIn the first episode of this special three-part series, Drs. Skolnik and Russell discuss the impact of diabetes on influenza-related morbidity, mortality, and adverse events. Beumer MC, Koch RM, van Beuningen D, OudeLashof AM, van de Veerdonk FL, Kolwijck E, van der Hoeven JG, Bergmans DC, Hoedemaekers CWE. Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality. J Crit Care. 2019 Apr;50:59-65. doi: 10.1016/j.jcrc.2018.11.013. Epub 2018 Nov 15. PMID: 30481669; PMCID: PMC7125534. Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. Am J Public Health. 1999 Nov;89(11):1715-21. doi: 10.2105/ajph.89.11.1715. PMID: 10553394; PMCID: PMC1508989. Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. Diabetes Metab J. 2019 Jun;43(3):319-341. doi: 10.4093/dmj.2018.0060. PMID: 31210036; PMCID: PMC6581547. In episodes 2 and 3, Drs. Skolnik and Russell will take a closer look into the influenza-related complications in persons with diabetes and will discuss the important role that clinicians play in improving vaccination rates among patients with diabetes. This special three-part series on influenza and diabetes is supported by an unrestricted educational grant from Sanofi Pasteur, the vaccines global business unit of Sanofi. |
|
Diabetes Core Update June 2020 Post Date: May 31, 2020 |
Discussed in This EpisodeThe Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Kwon et al. Diabetes Care 2020 June; 43(6). https://doi.org/10.2337/dc19-0936 Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes. Ali et al. Diabetes Care 2020 June; 43(6). https://doi.org/10.2337/dc18-2460 Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. Liakopoulos et al. Diabetes Care 2020 June; 43(6). https://doi.org/10.2337/dc19-1703 Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Hartman et al. Diabetes Care 2020 June; 43(6). https://doi.org/10.2337/dc19-1892 Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey. Le et al. Diabetes Care 2020 June; 43(6). https://doi.org/10.2337/dc19-2424 A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. Sesti, G, Bardtrum, L, Dagdelen, S, et al. Diabetes Obes Metab. 2020; 22: 873– 878. https://doi.org/10.1111/dom.13957 A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. Kelly et al. N Engl J Med. 2020; 382:2117-2128. https://doi.org/10.1056/NEJMoa1916038 |
|
Post Date: May 25, 2020 |
Discussed in This EpisodeIn this special episode, Dr. Boris Draznin (University of Colorado, Denver), along with a distinguished panel, focuses on inpatient care for people with diabetes and COVID-19, utilizing a question and answer format, during a town hall. This episode was originally recorded on May 14, 2020, and presented as part of ADA’s COVID-19 webinar series. Boris Draznin, MD, PhD Carol Levy, MD, CDE Jing Chao, MD Related resources: Town Hall: Real-World Cases--Inpatient Care for People with Diabetes and COVID-19 |
|
How Do HCPs Safely Reopen Their Practice After COVID-19 Quarantine? Post Date: May 21, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Neil Skolnik (Thomas Jefferson University) and John B. Lynch (University of Washington), discuss how health care providers can safely reopen their practices after the COVID-19 quarantine. This episode was originally recorded on May 14, 2020, and presented as part of ADA’s COVID-19 webinar series. Neil Skolnik, MD John B. Lynch, MD, MPH Related resources: How Do HCPs Safely Reopen Their Practice After COVID-19 Quarantine? |
|
Diabetes Core Update: COVID-19 - Challenges and Opportunities to Help Vulnerable Populations Post Date: May 19, 2020 |
Discussed in This EpisodeIn this special episode, Dr. Enrique Caballero (Harvard Medical School), along with a distinguished panel, focuses on the challenges and opportunities to help vulnerable populations. This episode was originally recorded on April 23, 2020, and presented as part of ADA’s COVID-19 webinar series. Enrique Caballero, MD Ashby Walker, PhD Anne Harper, MS, RDN, CDE Lisa Taylor, DNP, MSN, BSN Arshiya A. Baig, MD, MPH, FACP Related resources: COVID-19 and the Diabetes Care Team: Challenges and Opportunities to Help Vulnerable Populations |
|
Diabetes Core Update: COVID-19 and Diabetes Technology - Updates Post Date: May 12, 2020 |
Discussed in This EpisodeIn this special episode, Dr. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) along with a distinguished panel, focuses on Diabetes Technology in the COVID-19 outbreak. This episode was originally recorded on May 12, 2020, and presented as part of ADA’s COVID-19 webinar series. Irl B. Hirsch, MD Ruth S. Weinstock, MD, PhD Davida F. Kruger, MSN, APN-BC, BC-ADM Related resources: |
|
Diabetes Core Update: COVID-19 - The Role of Community Health Workers as First Responders Post Date: May 9, 2020 |
Discussed in This EpisodeIn this special episode, Dr. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and Betsy Rodriguez (Centers for Disease Control and Prevention), along with a distinguished panel, focuses on the role of community health workers as first responders in the COVID-19 outbreak. This episode was originally recorded on May 5, 2020, and presented as part of ADA’s COVID-19 webinar series. Betsy Rodriguez Colleen Barbero, PhD Denise Octavia Smith, MBA, CHW, PN, SFC Related resources: The Role of Community Health Workers as First Responders in the COVID-19 Outbreak |
|
Post Date: May 5, 2020 |
Discussed in This EpisodeThe Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Kwon et al. Diabetes Care 2020 May; 43(5). https://doi.org/10.2337/dc19-0936 Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes. Gopalan et al. Diabetes Care 2020 May; 43(5). https://doi.org/10.2337/dc19-1380 Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Garvey et al. Diabetes Care 2020 May; 43(5). https://doi.org/10.2337/dc19-1745 Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. Sukkar et al. Diabetes Care 2020 May; 43(5). https://doi.org/10.2337/dc19-1803 Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes. Mita T, Osonoi Y, Osonoi T, et al. BMJ Open Diabetes Research and Care 2020;8:e001162. 10.1136/bmjdrc-2019-001162 Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. hieu, VT, Mitchell, BD, Varnado, OJ, Frier, BM. Diabetes Obes Metab. 2020; 22: 469– 479. https://doi.org/10.1111/dom.13941 |
|
Diabetes Core Update: COVID-19 - Impact on Youth and their Families Post Date: May 3, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and Cynthia Munoz (President-Elect, Health Care & Education, American Diabetes Association), along with a distinguished panel, discuss the impact COVID-19 is having on youth with diabetes and their families. This episode was originally recorded on April 29, 2020, and presented as part of ADA’s COVID-19 webinar series. Barry Conrad, MPH, RD, CDE Marisa Hilliard, PhD Cynthia Munoz, PhD, MPH Jennifer Raymond, MD, MCR Related resources: COVID-19: Impact on Youth with Diabetes & Families in Quarantine |
|
Diabetes Core Update: COVID-19 - Older Adults Post Date: April 26, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Irl Hirsch (University of Washington), Elbert Huang (University of Chicago), and Stacie Levine (University of Chicago) discuss issues related to treating older adults with diabetes and COVID-19. This episode was originally recorded on April 20, 2020, and presented as part of ADA’s COVID-19 webinar series. Topics include: 1. Risk of COVID-19 in older adults 2. What are the recommendations for glucose control during the pandemic 3. Telemedicine 4. Challenges to home care 5. Long-term care settings Related resources: |
|
Diabetes Core Update: COVID-19 - Cardiovascular Concerns Post Date: April 25, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and John Russell (Thomas Jefferson University and Abington Jefferson Health) discuss cardiovascular concerns in patients with COVID-19 and diabetes. This episode was originally recorded on April 19, 2020, and presented as part of ADA’s COVID-19 webinar series. Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health Related resources: |
|
Diabetes Core Update: COVID-19 - Empowering Patients Post Date: April 25, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Mary de Groot (ADA President, Health Care & Education; Indiana University School of Medicine), Jane Jeffrie Seley (New York Presbyterian Hospital/Weill Cornell Medicine Center), and Jean M. Lawrence (Southern California Permanente Medical Group; Kaiser Permanente Research) discuss topics related to empowering patients with diabetes during COVID-19. This episode was originally recorded on April 9, 2020, and presented as part of ADA's webinar series. Topics include: 1. Defining terms and talking with patients about the epidemiology of COVID-19 2. How should providers talk with patients about the risk of COVID-19? The impact of testing 3. COVID-19 infection and its impact on self-care 4. Barriers to problem-solving 5. Diabetes self-care: helping to create a sense of normalcy 6. Diabetes self-care: “It’s OK not to be OK”; acknowledging our feelings 7. Coping with stress Related resources: |
|
Diabetes Core Update: COVID-19 - Self-Care Post Date: April 25, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and Aaron Sutton, LCSW (Behavioral Health Consultant; Abington Jefferson Health) discuss the often overlooked importance of caring for ourselves while caring for others. This episode was originally recorded on April 1, 2020, and presented as part of ADA’s COVID-19 webinar series. Neil Skolnik, MD Aaron Sutton, LCSW Related resources: |
|
Diabetes Core Update: COVID-19 - Telehealth Post Date: April 24, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and Eric Johnson (University of North Dakota School of Medicine and Health Sciences) discuss telehealth approaches to treating patients with diabetes during COVID-19. This episode was originally recorded on March 31, 2020, and presented as part of ADA’s COVID-19 webinar series. Neil Skolnik, MD Eric Johnson, MD Related resources: |
|
Diabetes Core Update: COVID-19 - Inpatient Townhall Post Date: April 24, 2020 |
Discussed in This EpisodeIn this special episode, distinguished faculty answer questions about inpatient management of patients who have diabetes, during COVID-19. This episode, which was recorded on April 7, 2020, is a follow-up discussion to ADA’s Town Hall on inpatient care for people with diabetes and is presented as part of ADA’s COVID-19 webinar series. Shivani Agarwal, MD, MPH Jennifer Clements, PharmD, FCCP, BCPS, CDE, BCACP Robert Eckel, MD Irl Hirsch, MD Melanie Mabrey, DNP Jane Jeffrie-Seley, DNP, BC-ADM, CDCES Neil Skolnik, MD Related resources: ADA Townhall: COVID-19 and Inpatient Care for People With Diabetes Inpatient Diabetes Care and COVID-19 |
|
Diabetes Core Update: COVID-19 - Inpatient Management #2 Post Date: April 23, 2020 |
Discussed in This EpisodeIn this special episode, Drs. Robert Eckel (ADA President, Medicine & Science), Mary Korytkowski (University of Pittsburgh), and Irl Hirsh (University of Washington) answer questions about inpatient diabetes care during COVID-19. This episode, which was recorded on April 15, 2020, is a follow-up discussion to ADA’s Town Hall on inpatient care for people with diabetes and is presented as part of ADA’s COVID-19 webinar series. Topics include: 1. Subcutaneous insulin infusions 2. CGM use in the inpatient setting 3. Insulin infusion pumps in the inpatient setting 4. Recommendations for inpatient glycemic control 5. Oral medications 6. Hydroxychloroquine and adverse effects in persons with diabetes Related resources: ADA Townhall: COVID-19 and Inpatient Care for People With Diabetes |
|
Diabetes Core Update: COVID-19 and Diabetes – Considerations for Health Care Professionals Post Date: April 23, 2020 |
Discussed in This EpisodeIn this special episode, the American Diabetes Association’s COVID-19 leadership team discusses a range of issues related to COVID-19 and the treatment of diabetes. This episode was originally recorded on March 31, 2020, and presented as part of ADA’s COVID-19 webinar series. Topics include:
1. Access to medications 2. Effect on diabetes self-management 3. Can patients take their own supplies (e.g., insulin pumps and CGM) if they are hospitalized? 4. Considerations for specific hypoglycemic medications during inpatient hospitalization 5. Differences in management for persons with type 1 and type 2 diabetes 6. Use of SGLT-2 inhibitors and GLP-1 receptor agonists during the COVID-19 infection 7. Diabetes and cardiovascular disease during COVID-19 8. ACEs and ARBs 9. Stress among healthcare professionals Robert Eckel, MD Mary de Groot, PhD Irl Hirsch, MD Anne Peters, MD Louis Philipson, MD, PhD Neil Skolnik, MD |
|
Diabetes Core Update: COVID-19 - Deep Dive into Medication Management Post Date: April 22, 2020 |
Discussed in This EpisodeThis special episode focuses on managing and monitoring diabetes patients’ medications during the COVID-19 pandemic. This episode was originally recorded on April 14, 2020, and presented as part of ADA’s COVID-19 webinar series. In this episode, Drs. Neil Skolnik (Sidney Kimmel Medical College, Thomas Jefferson University) and Joshua J. Neumiller (College of Pharmacy and Pharmaceutical Sciences, Washington State University) discuss the following topics: 1. Inpatient Medication Management for Persons Admitted With Diabetes 2. Outpatient Medication Management for Persons With Diabetes 3. Hypoglycemic Medication Management 4. ACEs and ARBs 5. NSAIDs Related resources: ADA Town Hall: COVID-19 and Inpatient Care for People With Diabetes COVID-19 and Diabetes – Considerations for Health Care Professionals |
|
Diabetes Core Update: COVID-19 - Inpatient Management of Persons with Diabetes Post Date: April 21, 2020 |
Discussed in This EpisodeThis special episode focuses on inpatient management of patients with diabetes and COVID-19 infection. In this episode, Drs Irl Hirsch (University of Washington, Seattle) and Guillermo E. Umpierrez (Emory University, Atlanta Georgia) discuss the following topics: 1. Risk with Diabetes of COVID-19 and Complications of COVID-19 2. Management of Hyperglycemia during COVID-19 Infection 3. Sub-cutaneous Insulin for DKA 4. CGM in the Hospital Setting 5. Home detection and care of DKA 6. Diabetes Education in the Hospital During COVID-19 |
|
Diabetes Core Update: COVID-19 - Planning Sick Days Post Date: April 20, 2020 |
Discussed in This EpisodeThis special episode on planning sick days for your diabetes patients during COVID-19 was originally recorded on April 1, 2020, and presented as part of ADA’s COIVID-19 webinar series. In this episode, Drs. Anne Peters (University of Southern California) and Louis Philipson (ADA Past President, Medicine & Science; University of Chicago) discuss the following topics: 1. How do we help our patients with diabetes stay safe during COVID-19? 2. Helping patients negotiate safety issues in the workplace 3. Safety Issues when people do not come in for care 4. Managing SGLT-2 inhibitors during the pandemic 5. Home detection and care of DKA 6. Renewing medications and telemedicine visits Related COVID-19 resources: COVID-19 and Diabetes: ADA Resources for Diabetes Professionals Diabetes and COVID-19 Online Community Information for Patients With Diabetes |
|
Diabetes Core Update: Therapeutic Inertia Series Episode #1 Post Date: April 14, 2020 |
Discussed in This EpisodeIn this first episode of a three-part series on “Disrupting Therapeutic Inertia in Diabetes Management,” Drs. John Russell and Neil Skolnik examine a case study of a 55-year-old man with type 2 diabetes (3 years duration, A1C 8.2%). In so doing, they review the following six articles that define achievement gaps in reaching A1C goals and the reasons for why those gaps exist: Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Khunti et al. Diabetes Research and Clinical Practice 2018 March; Vol. 137: 137-148. https://doi.org/10.1016/j.diabres.2017.12.004 Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016. Kazemian P, Shebl FM, McCann N, Walensky RP, Wexler DJ. JAMA Intern Med. 2019;179(10):1376–1385. doi:10.1001/jamainternmed.2019.2396 Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System. Pantalone et al. Diabetes Care 2016 Sep; 39(9): 1527-1534. https://doi.org/10.2337/dc16-0227 Clinical Inertia in People With Type 2 Diabetes. Khunti et al. Diabetes Care 2013 Nov; 36(11): 3411-3417. https://doi.org/10.2337/dc13-0331 Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Carls et al. Diabetes Care 2017 Nov; 40(11): 1469-1478. https://doi.org/10.2337/dc16-2725 Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. Blonde et al. Diabetes Spectrum 2019 May; 32(2): 93-103. https://doi.org/10.2337/ds17-0082 In episodes 2 and 3 of this series, Drs. Russell and Skolnik will look at additional causes of therapeutic inertia and solutions for overcoming it. This special three-part series on therapeutic inertia is supported by unrestricted educational grant from Sanofi. |
|
Diabetes Core Update April 2020 Post Date: March 31, 2020 |
Discussed in This EpisodeTime Course of Normalization of Functional β-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. Zhyzhneuskaya et al. Diabetes Care 2020 Jan; 43(1). https://doi.org/10.2337/dc19-0371 The Association Between Poor Glycemic Control and Health Care Costs in People With Diabetes: A Population-Based Study Mata-Cases et al. Diabetes Care 2020 Feb; 43(2). https://doi.org/10.2337/dc19-0573 Time Course of Normalization of Functional β-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. Tabaei et al. Diabetes Care 2020Feb; 43(2). https://doi.org/10.2337/dc19-0954 Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018 Dave et al. Diabetes Care 2020 Feb; 43(2). https://doi.org/10.2337/dc19-1943 Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Ferrannini et al. Diabetes Care 2020 Feb; 43(2). https://doi.org/10.2337/dc19-2165 Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial. Vilsbøll, T, Ekholm, E, Johnsson, E, et al. Diabetes Obes Metab. 2020; 1– 12. https://doi.org/10.1111/dom.13981 |
|
Special Edition: COVID-19 UPDATE Post Date: March 25, 2020 |
Discussed in This EpisodeCharacteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Wu Z, McGoogan JM. JAMA. Published online February 24, 2020. doi:10.1001/jama.2020.2648 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Zhou et al. The Lancet, In Press. Available online 11 March 2020 https://doi.org/10.1016/S0140-6736(20)30566-3 Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Fang et al. The Lancet, In Press. Available online 11 March 2020. https://doi.org/10.1016/S2213-2600(20)30116-8 |
|
Diabetes Core Update March 2020 Post Date: February 24, 2020 |
Discussed in This EpisodeA Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study. Frykberg et al. Diabetes Care 2020 Mar; 43(3): 616-624. https://doi.org/10.2337/dc19-0476 Severe Hypoglycemia and Cognitive Function in Older Adults With Type 1 Diabetes: The Study of Longevity in Diabetes (SOLID). Lacy et al. Diabetes Care 2020 Mar; 43(3): 541-548. https://doi.org/10.2337/dc19-0906 Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure. Aminian et al. Diabetes Care 2020 Mar; 43(3): 534-540. https://doi.org/10.2337/dc19-1057 The Prevalence and Determinants of Cognitive Deficits and Traditional Diabetic Complications in the Severely Obese. Callaghan et al. Diabetes Care 2020 Mar; 43(3): 683-690. https://doi.org/10.2337/dc19-1642 Association of BMI, Fitness, and Mortality in Patients With Diabetes: Evaluating the Obesity Paradox in the Henry Ford Exercise Testing Project (FIT Project) Cohort. Whelton et al. Diabetes Care 2020 Mar; 43(3): 677-682. https://doi.org/10.2337/dc19-1673 Nutrient-Induced Metabolic Stress, Adaptation, Detoxification, and Toxicity in the Pancreatic β-Cell. Prentki et al. Diabetes 2020 Mar; 69(3): 279-290. https://doi.org/10.2337/dbi19-0014 |
|
Diabetes Core Update February 2020 Post Date: January 25, 2020 |
Discussed in This EpisodeEmpagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Kahl et al. Diabetes Care 2020 Feb; 43(2): 298-305. https://doi.org/10.2337/dc19-0641 Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. Younossi et al. Diabetes Care 2020 Feb; 43(2): 283-289. https://doi.org/10.2337/dc19-1113 Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study. Cahn et al. Diabetes Care 2020 Feb; 43(2): 468-475. https://doi.org/10.2337/dc19-1476 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Buse et al. Diabetes Care 2020 Feb; 43(2): 487-493. https://doi.org/10.2337/dci19-0066 Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients. Blumer et al. Clinical Diabetes 2019 Oct; 37 (4): 386-390. https://doi.org/10.2337/cd18-0102 Positive reinforcement by general practitioners is associated with greater physical activity in adults with type 2 diabetes. Geerling et al. BMJ Open Diabetes Research and Care 2019;7:e000701. https://drc.bmj.com/content/7/1/e000701 |
|
Diabetes Core Update January 2020 Post Date: December 26, 2019 |
Discussed in This EpisodeAbsence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study. Carlsson et al. Diabetes Care 2020 Jan; 43(1): 82-89. https://doi.org/10.2337/dc19-0747 Reports of Lactic Acidosis Attributed to Metformin, 2015–2018. Flory et al. Diabetes Care 2020 Jan; 43(1): 244-246. https://doi.org/10.2337/dc19-0923 Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Pettus et al. Diabetes Care 2020 Jan; 43(1): 161-168. https://doi.org/10.2337/dc19-1328 Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Hampp et al. Diabetes Care 2020 Jan; 43(1): 90-97. https://doi.org/10.2337/dc19-1481 Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes. Lega et al. Diabetes Obes Metab. 2019; 21: 2394– 2404. https://doi.org/10.1111/dom.13820 Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Ledesma et al. Diabetes Obes Metab. 2019; 21: 2465– 2473. https://doi.org/10.1111/dom.13829 |
|
Diabetes Core Update December 2019 Post Date: November 26, 2019 |
Discussed in This EpisodeResidual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. Fan et al. Diabetes Care 2019 Dec; 42(12): 2307-2314. https://doi.org/10.2337/dc19-0501 Changes in Consumption of Sugary Beverages and Artificially Sweetened Beverages and Subsequent Risk of Type 2 Diabetes: Results From Three Large Prospective U.S. Cohorts of Women and Men. Drouin-Chartier et al. Diabetes Care 2019 Dec; 42(12): 2181-2189. https://doi.org/10.2337/dc19-0734 Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study. Critchley et al. Diabetes Care 2019 Dec; 42(12): 2237-2246. https://doi.org/10.2337/dc19-0848 Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Rodbard et al. Diabetes Care 2019 Dec; 42(12): 2272-2281. https://doi.org/10.2337/dc19-0898 A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal‐bolus insulin or a glucagon‐like peptide‐1 receptor agonist plus basal insulin: The SIMPLE study. Abreu et al. Diabetes, Obesity and Metabolism 2019. Published Online May 30, 2019. https://doi.org/10.1111/dom.13794 |
|
Diabetes Core Update November 2019 Post Date: October 30, 2019 |
Discussed in This EpisodeNationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Lee et al. Diabetes Care 2019 Nov; 42(11): 2057-2064. https://doi.org/10.2337/dc18-2195 Long-term Effects of Disasters on Seniors With Diabetes: Evidence From Hurricanes Katrina and Rita. Quast et al. Diabetes Care 2019 Nov; 42(11): 2090-2097. https://doi.org/10.2337/dc19-0567 Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Wexler et al. Diabetes Care 2019 Nov; 42(11): 2098-2107.https://doi.org/10.2337/dc19-0901 Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Blonde et al. Diabetes Care 2019 Nov; 42(11): 2108-2116.https://doi.org/10.2337/dc19-1357 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Husain et al. N Engl J Med 2019. Published Online August 29, 2019. https://doi.org/10.1056/NEJMoa1901118 Sodium‐glucose co‐transporter inhibitors: Medications that mimic fasting for cardiovascular prevention Giaccari et al. Diabetes, Obesity and Metabolism 2019. Published Online June 17, 2019. https://doi.org/10.1111/dom.13814 |
|
Diabetes Core Update October 2019 Post Date: September 24, 2019 |
Discussed in This EpisodeIncidence of Type 2 Diabetes in People With a History of Hospitalization for Major Mental Illness in Scotland, 2001–2015: A Retrospective Cohort Study. Jackson et al. Diabetes Care 2019 Oct; 42(10): 1879-1885. https://doi.org/10.2337/dc18-2152 Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. Sardu et al. Diabetes Care 2019 Oct. Diabetes Care 2019 Oct; 42(10): 1946-1955. https://doi.org/10.2337/dc18-2356 Change in Cardiovascular Health and Incident Type 2 Diabetes and Impaired Fasting Glucose: The Whitehall II Study. Climie et al. Diabetes Care 2019 Oct; 42(10): 1981-1987. https://doi.org/10.2337/dc19-0379 Prospective Association Among Diabetes Diagnosis, HbA1c, Glycemia, and Frailty Trajectories in an Elderly Population. Aguayo et al. Diabetes Care 2019 Oct; 42(10): 1903-1911. https://doi.org/10.2337/dc19-0497 Nasal Glucagon: A Promising New Way to Treat Severe Hypoglycemia. Lynn H. Nguyen and John R. White Jr. Clinical Diabetes 2019 Jul; 37(3): 292-293. https://doi.org/10.2337/cd19-0013 Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. Blonde et al. Diabetes Spectrum 2019 May; 32(2): 93-103. https://doi.org/10.2337/ds17-0082 |
|
Diabetes Core Update September 2019 Post Date: August 24, 2019 |
Discussed in This EpisodeThe Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes, and Prediabetes. Dall et al. Diabetes Care 2019 Apr.; 42(4):1661-1668. https://doi.org/10.2337/dc18-1226 Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Tromp et al. Diabetes Care 2019 Sep; 42(9):1792-1799. https://doi.org/10.2337/dc18-2515 Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes. Guo et al. Diabetes Care 2019 Sep; 42(9): 1692-1699. https://doi.org/10.2337/dc19-0480 Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. The RISE Consortium. Diabetes Care 2019 Sep; 42(9): 1742-1751. https://doi.org/10.2337/dc19-0556 Lifestyle Counseling and Long-term Clinical Outcomes in Patients With Diabetes. Zhang et al. Diabetes Care 2019 Sep; 42(9): 1833-1836. https://doi.org/10.2337/dc19-0629 PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Aroda et al. Diabetes Care 2019 Sep; 42(9): 1724-1732. https://doi.org/10.2337/dc19-0749 |
|
Diabetes Core Update August 2019 Post Date: July 24, 2019 |
Discussed in This EpisodeDapagliflozin Plus Saxagliptin Add-on Therapy Compared with Insulin in Patients with Type 2 Diabetes Poorly Controlled by Metformin with or without Sulfonylurea Therapy: A Randomized Clinical Trial. Vilsboll et al. Diabetes Care 2019 Aug; 42(8):1464-1472. https://doi.org/10.2337/dc18-1988 Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. Basterra-Gortari et al. Diabetes Care 2019 Aug; 42(8):1390-1397. https://doi.org/10.2337/dc18-2475 Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Bril et al. Diabetes Care 2019 Aug; 42(8): 1481-1488. https://doi.org/10.2337/dc19-0167 Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Aroda et al. Lancet 2019. Published Online June 9, 2019. https://doi.org/10.1016/S2213-8587(19)30184-6 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Gerstein et al. Lancet Diabetes Endocrinol 2019. Published Online June 10, 2019. https://doi.org/10.1016/S0140-6736(19)31149-3 Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Partley et al. Lancet 2019. Published June 08, 2019. https://doi.org/10.1016/S0140-6736(19)31271-1 |
|
Diabetes Core Update July 2019 Post Date: June 19, 2019 |
Discussed in This EpisodeEffect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Yaronet et al. Diabetes Care 2019 Jul; 42 (7): 1178-1184. https://doi.org/10.2337/dc18-0166 Glucose Variations During Driving in People With Type 1 Diabetes Using a Continuous Glucose Monitoring System. Schmied and Zulewski. Diabetes Care 2019 Jul; 42 (7): 1340-1343. https://doi.org/10.2337/dc18-0822 Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up. Elliott et al. Diabetes Care 2019 Jul; 42 (7): 1290-1296. https://doi.org/10.2337/dc18-2266 Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Bode et al. Diabetes Care 2019 Jul; 42 (7): 1255-1262. https://doi.org/10.2337/dc19-0009 Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes. Mokhlesi et al., for the RISE Consortium. Diabetes Care 2019 Jul; 42 (7): 1326-1332. https://doi.org/10.2337/dc19-0298 Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Bersoff-Matcha et al. Ann Intern Med. 2019;170(11):764-769. https://doi.org/10.7326/M19-0085 |
|
Diabetes Core Update June 2019 Post Date: May 24, 2019 |
Discussed in This EpisodeBiochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. Patel et al. Diabetes Care 2019 Jun; 42 (6): 1132-1135. https://doi.org/10.2337/dc18-1453 Nonadherence to Insulin Therapy Detected by Bluetooth-Enabled Pen Cap Is Associated With Poor Glycemic Control. Munshi et al. Diabetes Care 2019 Jun; 42 (6): 1129-1131. https://doi.org/10.2337/dc18-1631 Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Andersen et al. Diabetes Care 2019 Jun; 42 (6): 1095-1103. https://doi.org/10.2337/dc18-2158 Open AccessInternational Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Danne et al. Diabetes Care 2019 Jun; 42 (6): 1147-1154. https://doi.org/10.2337/dc18-2316 Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Riddle et al. Diabetes Care 2019 Jun; 42 (6): 1136-1146. https://doi.org/10.2337/dci19-0020 When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control. Umpierrez et al. Diabetes, Obesity and Metabolism 2019 Feb. https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13653 |
|
►Diabetes Core Update May 2019 Post Date: April 26, 2019 |
Discussed in This EpisodeEffect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Salas-Salvadó et al. for the PREDIMED-Plus investigators. Diabetes Care 2019 May; 42(5): 777-788. https://doi.org/10.2337/dc18-0836 Randomized Trial of a Tailored Cognitive Behavioral Intervention in Type 2 Diabetes with Comorbid Depressive and/or Distress Symptoms—Twelve-Month Outcomes from COMRADE (Abstract). Cummings et al. Diabetes 2018 Jul; 67(Supplement 1). https://doi.org/10.2337/db18-867-P Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial. Kyi et al. Diabetes Care 2019 May; 42(5): 832-840. https://doi.org/10.2337/dc18-2342 Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Evert et al. Diabetes Care 2019 May; 42(5): 731-754. https://doi.org/10.2337/dci19-0014 Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Zelniker et al. Circulation. 2019;139:2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868 When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control. Umpierrez et al. Diabetes, Obesity and Metabolism 2019. https://doi.org/10.1111/dom.13653 (Epub at https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13653.) |
|
►Diabetes Core Update April 2019 Post Date: March 26, 2019 |
Discussed in This EpisodeEarly Detection of Hypoglycemia in Type 1 Diabetes Using Heart Rate Variability Measured by a Wearable Device. Bekkink et al. Diabetes Care https://doi.org/10.2337/dc18-1843 |
|
►Diabetes Core Update March 2019 Post Date: February 25, 2019 |
Discussed in This EpisodeThe legacy effect in type 2 diabetes: Impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care https://doi.org/10.2337/dc17-1144 Eye care utilization among insured people with diabetes in the U.S. 2010-2014. Diabetes Care https://doi.org/10.2337/dc18-0828 Hyperglycemia & Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS): Maternal gestational diabetes and childhood glucose metabolism. Diabetes Care https://doi.org/10.2337/dc18-1646 A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care https://doi.org/10.2337/dc18-1760 Oral semaglutide. Clinical Diabetes https://doi.org/10.2337/cd18-0034 Patient commitment and its relationship to A1C. Clinical Diabetes https://doi.org/10.2337/cd18-0003 |
|
►Diabetes Core Update February 2019 Post Date: January 24, 2019 |
Topics Covered in this EditionParticipating in mental, social and physical leisure activities and having a rich social network reduces the incidence of diabetes-related dementia in a cohort of Swedish older adults. https://doi.org/10.2337/dc18-1428 Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, including Dapagliflozin, is Consistent Across the Class: an Analysis of the Placebo Arm of EXSCEL http://doi.org/10.2337/dc18-1871 Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease https://doi.org/10.2337/dbi18-0007 Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study https://doi.org/10.1136/bmj.k3359 Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study https://doi.org/10.1136/bmj.k2693 Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus https://doi.org/10.1056/NEJMoa1804989 |
|
►Diabetes Core Update January 2019 Post Date: December 26, 2018 |
Topics Covered in this EditionLinagliptin Cardiovascular Outcome Trial (CARMELINA) |
|
►Diabetes Core Update December 2018 Post Date: December 1, 2018 |
Articles Covered in this EditionAn Automated Grading System for Vision-Threatening Referable Diabetic Retinopathy Detection based on Color Fundus Photographs http://doi.org/10.2337/dc18-0147 Evaluation and management of youth-onset type 2 diabetes: A statement of the American Diabetes Association http://doi.org/10.2337/dci18-0052 Older Adults and Diabetes Prevention Programs in the Veterans Health Administration http://doi.org/10.2337/dc18-1141 Impact of Gastric Banding versus Metformin on β-Cell Function in Adults with Impaired Glucose Tolerance or Mild Type 2 Diabetes http://doi.org/10.2337/dc18-1662 Paternal Exercise Improves Glucose Metabolism in Adult Offspring http://doi.org/10.2337/db18-0667 Glucagon-Like Peptide-1 Increases Beta Cell Regeneration by Promoting Alpha- to Beta-Cell Transdifferentiation http://doi.org/10.2337/db18-0155 |
|
►Diabetes Core Update November 2018 Post Date: November 1, 2018 |
Articles Covered in this EditionTrends and Disparities in Cardiovascular Mortality Among U.S. Adults With and Without Self-Reported Diabetes, 1988–2015 |
|
►Diabetes Core Update October 2018 Post Date: October 1, 2018 |
Articles Covered in this EditionLong-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance Time to treatment intensification and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes following monotherapy failure. Glycaemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study More similarities than differences testing insulin glargine 300 U/mL versus insulin degludec 100 U/mL in insulin-naïve type 2 diabetes: The randomized head-to-head BRIGHT trial Glycemic Variation and Cardiovascular Risk in the Veteran's Affairs Diabetes Trial LDL-cholesterol rises with body mass index only in lean individuals: cross-sectional US and Spanish representative data |
|
►Diabetes Core Update Sep 2018 Post Date: Aug 25, 2018 |
Articles Covered in this EditionA 26-week, randomized, controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (The DEPICT-2 study): 24-Week Results from a Randomized Controlled Trial Sotagliflozin in Combination with Optimized Insulin Therapy in Adults with Type 1 Diabetes: The North American inTandem1 Study Poor Glycemic Control is Associated with Increased Extracellular Volume Fraction in Diabetes |
|
►Diabetes Core Update Aug 2018 Post Date: July 25, 2018 |
Articles Covered in this EditionA Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors National Rates of Initiation and Intensification of Antidiabetic Therapy Among Patients With Commercial Insurance Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride |
|
►Diabetes Core Update July 2018 Post Date: June 25, 2018 |
Articles Covered in this EditionHealth Care Spending on Diabetes in the U.S., 1996–2013 Diabetes-Attributable Nursing Home Costs for Each U.S. State Risk of Type 2 Diabetes Among Lesbian, Bisexual, and Heterosexual Women: Findings From the Nurses’ Health Study II Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications Freestyle Libre Glucose Monitoring System |
|
►Diabetes Core Update June 2018 Post Date: May 24, 2018 |
Articles Covered in this EditionInfluence of Diabetes on Trends in Perioperative Cardiovascular Events The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery Postoperative Death After Lower-Limb Amputation in a National Prevalent Cohort of Patients With Diabetes Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks Insulin Access and Affordability Working Group: Conclusions and Recommendations |
|
►Diabetes Core Update May 2018 Post Date: April 24, 2018 |
Articles Covered in this EditionEfficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial Magnitude and Pattern of Placebo Response in Clinical Trials of Oral Antihyperglycemic Agents: Data From the U.S. Food and Drug Administration, 1999–2015 Prevalence of Major Behavioral Risk Factors for Type 2 Diabetes Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark Obesity Progression Between Young Adulthood and Midlife and Incident Diabetes: A Retrospective Cohort Study of U.S. Adults Economic Costs of Diabetes in the U.S. in 2017 |
|
►Diabetes Core Update April 2018 Post Date: April 4, 2018 |
Articles Covered in this EditionClinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study A Low-Fat Dietary Pattern and Diabetes: A Secondary Analysis From the Women’s Health Initiative Dietary Modification Trial Long-term Diet Quality and Risk of Type 2 Diabetes Among Urban Chinese Adults The Impact of Diabetes on Breast Cancer Treatments and Outcomes: A Population-Based Study Effect of A1C and Glucose on Postoperative Mortality in Noncardiac and Cardiac Surgeries Duration of Diabetes and Prediabetes During Adulthood and Subclinical Atherosclerosis and Cardiac Dysfunction in Middle Age: The CARDIA Study |
|
►Diabetes Core Update March 2018 Post Date: February 26, 2018 |
Articles Covered in this EditionEffect of Changing Work Stressors and Coping Resources on the Risk of Type 2 Diabetes: The OHSPIW Cohort Study Objectively Measured Physical Activity and Sedentary Time Are Associated With Cardiometabolic Risk Factors in Adults With Prediabetes: The PREVIEW Study Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study |
|
►Diabetes Core Update February 2018 Post Date: January 30, 2018 |
Articles Covered in this EditionIncretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Increased Liver Fatty Acid Uptake Is Partly Reversed and Liver Fat Content Normalized After Bariatric Surgery How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial |
|
►Diabetes Core Update January 2018 Post Date: December 28, 2017 |
Articles Covered in this EditionThe Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction The Effect of Telemedicine Follow-up Care on Diabetes-Related Foot Ulcers: A Cluster-Randomized Controlled Noninferiority Trial Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum |
|
Diabetes Core Update December 2017 Post Date: November 28, 2017 |
Articles Covered in this EditionIncidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study Time Trends of Dietary and Lifestyle Factors and Their Potential Impact on Diabetes Burden in China Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and Without Kidney Disease Risk Factors for Severe Hypoglycemia in Black and White Adults With Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP International Consensus on Use of Continuous Glucose Monitoring Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: Why Weight Loss Maintenance Is Difficult |
|
Diabetes Core Update November 2017 Post Date: October 24, 2017 |
Articles Covered in this EditionElevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance—The Maastricht Study Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events |
|
Diabetes Core Update October 2017 Post Date: October 4, 2017 |
Articles Covered in this EditionLow-Dose Persistent Organic Pollutants Impair Insulin Secretory Function of Pancreatic β-Cells: Human and In Vitro Evidence Genetic Susceptibility, Change in Physical Activity, and Long-term Weight Gain A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC’s National Diabetes Prevention Program All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial The Changing Tides of the Type 2 Diabetes Epidemic—Smooth Sailing or Troubled Waters Ahead? Kelly West Award Lecture 2016 |
|
Special Edition: Diabetes Is Primary 2017 Part 2 Post Date: September 13, 2017 |
Special EditionDiabetes Is Primary 2017 Find complete versions of the Diabetes Is Primary lectures and earn CE credit for free online at https://ada.healthmonix.com/. |
|
Diabetes Core Update September 2017 Post Date: August 29, 2017 |
Articles Covered in this EditionComputed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes Hemoglobin A1c Variability Predicts Symptoms of Depression in Elderly Individuals With Type 2 Diabetes A Team-Based Online Game Improves Blood Glucose Control in Veterans With Type 2 Diabetes: A Randomized Controlled Trial Diabetes and Hypertension: A Position Statement by the American Diabetes Association DASH Eating Plan: An Eating Pattern for Diabetes Management Ways Health Care Providers Can Promote Better Medication Adherence |
|
Special Edition: Diabetes Is Primary 2017 Part 1 Post Date: August 15, 2017 |
Special EditionDiabetes Is Primary 2017 Find complete versions of the Diabetes Is Primary lectures and earn CE credit for free online at https://ada.healthmonix.com/. |
|
Diabetes Core Update August 2017 Post Date: July 26, 2017 |
Articles Covered in this EditionMaternal Exercise Improves Glucose Tolerance in Female Offspring An Interrupted Time Series Analysis to Determine the Effect of an Electronic Health Record–Based Intervention on Appropriate Screening for Type 2 Diabetes in Urban Primary Care Clinics in New York City Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes Mediterranean Eating Pattern Presented at ADA's Scientific Sessions: Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial |
Citation Information
To cite information from a podcast, use the following format: "Author name(s): Article title (article DOI). Podcast Series Name [podcast], day month year available. Speaker name(s) (host). URL from which Podcast was retrieved"
For example, Yeh H.-C., et al.: A prospective study of the associations between treated diabetes and cancer outcomes (doi:10.2337/dc11-0225). Diabetes Core Update [podcast], 6 March 2012. Skolnik N, Russell J (hosts). Podcast retrieved from http://www.diabetesjournals.org/content/diabetes-core-update-podcasts